Quantcast

Latest Epirubicin Stories

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-11-13 13:23:44

Phase III trial examines pathological complete response rate Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these...

2011-12-07 14:36:01

One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)´, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients². "These studies open the way for the early identification of myocardial damage at the subclinical level, thereby...

2010-04-15 11:35:00

PITTSBURGH, April 15 /PRNewswire/ -- Precision Therapeutics will present two abstracts at the upcoming American Association for Cancer Research (AACR) meeting to be held in Washington, D.C. April 17-21. Using 27 different breast cancer cell lines, the abstract titled, "Identification of Multi-Drug Response Genes by Meta-Analysis based on ChemoFx® in Human Breast Cancer Cell Lines," identified genes which are associated with response to different drugs, and genes...

2010-01-25 07:11:48

Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. Despite their resistance to drugs of the anthracycline class, the breast cancers bearing this gene signature will probably still be vulnerable to other types of chemotherapy agents, say scientists in a letter to be published in Nature Medicine on its Web site and later in a...

2009-12-14 10:54:00

ROCKAWAY, N.J., Dec. 14 /PRNewswire/ -- The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.(2) According to the INS...

2009-11-11 02:00:00

Finland, November 11 /PRNewswire/ -- - This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 November 2009. - FinXX, a Large, Phase III Randomised Study in Women With Early Breast Cancer Shows that Adding Capecitabine (Xeloda(R)) to a Treatment Regimen Containing Standard Agents Allows More Women to Live Cancer-Free for Longer An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology...

2009-09-23 06:15:00

BERLIN, September 23 /PRNewswire/ -- - The Austrian Breast and Colorectal Cancer Study Group Present Data Which Highlight Benefits of Adding capecitabine to epirubicin and docetaxel in the Neoadjuvant Setting Data from the ABCSG-24 study presented today at the joint 15th ECCO and 34th ESMO congress in Berlin, Germany, show that adding capecitabine (Xeloda(R)) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) completely eradicated the tumour...

2009-08-05 10:16:00

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market for these two products approximated $25 million in 2008. Sagent will begin marketing and shipping both products immediately. "We are very pleased to begin expanding our product line to include vital oncology...

2009-01-23 09:41:54

Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth. Their findings, reported online this week at the Proceedings of the National Academy of Sciences Early Edition, suggest that a subgroup of cancer patients might particularly benefit from these drugs.The anthracycline class of chemotherapeutics "” doxorubicin (Adriamycin), daunorubicin, epirubicin, idarubicin "” have been used...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related